Particle Design for Taste-Masking Using a Spray-Congealing Technique
スポンサーリンク
概要
- 論文の詳細を見る
A method of taste-masking using a spray-congealing technique was developed. Clarithromycin (CAM), a macloride antibiotic with a bitter taste, was selected as the model compound. The fundamental objective was to prevent the preparation from dissolving in the mouth, while ensuring that rapid release of CAM from the preparation could be attained in the gastrointestinal tract, resulting in bioequivalence to the conventional dosage form. Glyceryl monostearate (GM) and aminoalkyl methacrylate copolymer E (AMCE) were selected as ingredients, since GM, a substance with a low melting point, is able to be decomposed by an enzymatic reaction in the intestinal tract where the solubility of AMCE is very low. On the other hand, AMCE was selected because it is freely soluble at low pH levels (e.g. the pH level in the stomach), but insoluble in neutral and high pH levels (e.g. the pH level in the mouth).Spherical particles of the matrix (spherical matrix) and disks of matrix with various ratios were prepared, and the optimum ratios of CAM, GM and AMCE for the following release criterion were determined by experimental design (the simplex method). That is, 100 mg/l of CAM in the spherical matrix should be completely released within 20 min in pH 4.0,and less than 14 mg/l of CAM in spherical matrix should be released at 60 min in pH 6.5.As a result, the optimum formula for the matrix in consistency with the criterion was 3 : 6 : 1 for CAM, GM and AMCE, respectively.
- 公益社団法人日本薬学会の論文
- 1996-01-15
著者
-
Nemoto M
Department Of Pharmaceutics Research Center Taisho Pharmaceutical Co. Ltd.
-
Nemoto Masami
Division Of Diabetes Metabolism And Endocrinology Department Of Internal Medicine Jikei University S
-
Nemoto Masami
Department Of Pharmaceutics Research Center Taisho Pharmaceutical Co. Ltd.
-
Itai S
Pharmaceutics Laboratory Medicinal Research Laboratories Taisho Pharmaceutical Co. Ltd.
-
Yajima T
Pharmaceutics Laboratory Medicinal Research Laboratories Taisho Pharmaceutical Co. Ltd.
-
YAJIMA Toshio
Department of Pharmaceutics, Research Center, Taisho Pharmaceutical Co., Ltd.,
-
UMEKI Nobuo
Department of Pharmaceutics, Research Center, Taisho Pharmaceutical Co., Ltd.,
-
ITAI Shigeru
Department of Pharmaceutics, Research Center, Taisho Pharmaceutical Co., Ltd.,
-
NOGATA Akemi
Department of Pharmaceutics, Research Center, Taisho Pharmaceutical Co., Ltd.
-
DEMACHI Miki
Department of Pharmaceutics, Research Center, Taisho Pharmaceutical Co., Ltd.
-
YUNOKI Nobuo
Department of Pharmaceutics, Research Center, Taisho Pharmaceutical Co., Ltd.
-
Demachi Miki
Department Of Pharmaceutics Research Center Taisho Pharmaceutical Co. Ltd.
-
Umeki N
Taisho Pharmaceutical Co. Ltd. Saitama Jpn
-
Nogata Akemi
Department Of Pharmaceutics Research Center Taisho Pharmaceutical Co. Ltd.
-
Yunoki Nobuo
Department Of Pharmaceutics Research Center Taisho Pharmaceutical Co. Ltd.
-
Yajima T
Department Of Pharmaceutics Research Center Taisho Pharmaceutical Co. Ltd.
-
Itai Shigeru
Department of Pharmaceutical Engineering, School of Pharmaceutical Sciences, University of Shizuoka
関連論文
- PPARγ2 Pro12Ala Polymorphism and Insulin Resistance in Japanese Hypertensive Patients
- In Vitro Dissolution Tests Corresponding to the in Vivo Dissolution of Clarithromycin Tablets in the Stomach and Intestine
- A New Pharmacokinetic Model Including in Vivo Dissolution and Gastrointestinal Transit Parameters
- Direct Transport of 2', 3'-Didehydro-3'-deoxythymidine (D4T) and Its Ester Derivatives to the Cerebrospinal Fluid via the Nasal Mucous Membrane in Rats
- Nasal Absorption of 2', 3'-Didehydro-3'-deoxythymidine (D4T) and Its Esters in Rats
- In vitro and Pathological Investigations of MODY5 with the R276X-HNF1β(TCF2) Mutation
- Formulation Design of an Oral, Fast-Disintegrating Dosage Form Containing Taste-Masked Particles of Famotidine
- Formulation Design of Taste-Masked Particles, Including Famotidine, for an Oral Fast-Disintegrating Dosage Form
- Preferential transmission of maternal allele with DQA1^*0301-DQB1^*0302 haplotype to affected offspring in families with type 1 diabetes
- Optimum Heat Treatment Conditions for Masking the Bitterness of the Clarithromycin Wax Matrix
- Determination of Optimum Processing Temperature for Transformation of Glyceryt Monostearate
- Method of Evaluation of the Bitterness of Clarithromycin Dry Syrup
- Optimum Spray Congealing Conditions for Masking the Bitter Taste of Clarithromycin in Wax Matrix
- Particle Design for Taste-Masking Using a Spray-Congealing Technique
- Determination of Useful Ranges of Mixing Conditions for Glycerin Fatty Acid Ester by Multiple Regression Analysis